Table 1.

Results of Recent Randomized Studies in Newly Diagnosed Myeloma

Trial	Regim en	No. of patie nts	Overa ll respo nse rate (%)	CR plus VGP R (%)	Progressi on-free survival (Median in months)	P value for progress ion free survival	3 year overa ll survi val rate (%)*	Overal l surviv al (Medi an in month s)*	P value for overa ll survi val
Rajku mar et al5	RD	223	81	50	19		75	NR
	Rd	222	70	40	25	0.026	74	NR	0.47
Durie et al6	Rd	232	72	32	30	0.004	75	64	0.002
	VRd	242	82	44	43		85	75
Morea u et al7	VCD	170	84	66	N/A		N/A	N/A	N/A
	VTD	170	92	77	N/A	N/A	N/A	N/A
Attal et al8	VRD	350	N/A	46% CR	NR; 48% @3 years		88% at 3 years	NR	0.25
	VRD- ASCT	350	N/A	58% CR	NR; 61% at 3 years	<0.001	88% at 3 years	NR

^*Estimated from survival curves when not reported

^**Progression free survival not reported, numbers indicate time to progression

^†Rd until progression versus MPT

Abbreviations: VTD, bortezomib, thalidomide, dexamethasone; VRD, bortezomib, lenalidomide plus dexamethasone; VCD, bortezomib, cyclophosphamide, dexamethasone; N/A, not available; NR, not reported; CR, complete response; VGPR, very good partial response.

Modified from Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc 2016;91:101–119